About Roar Biomedical

Roar Biomedical was established in 1997, and is located in New York City at Columbia University’s Audubon Biomedical Center. Roar supports drug discovery and clinical research by bringing new technologies to market, as well as through a variety of other research and development efforts.


Valuable, Novel Techniques

Roar develops, manufactures, and markets novel fluorescence-based methods. In addition to holding 15 U.S. and multiple international patents, our proprietary techniques are cited in over 200 scientific publications and 24 patents held by other entities. Additionally, Roar co-brands a number of products with MilliporeSigma.

Lipid Transfer Assays

Roar specializes in techniques to measure the activity of enzymes directly involved in lipid metabolism. These proteins play a central role in the development of cardiovascular and other diseases. Roar has licensed assays to several pharmaceutical companies, as well as holding non-commercial licensing agreements with over 75 academic institutions.

Supporting Clinical Trials

Roar’s innovations include plasma cholesteryl ester transfer protein (CETP) activity assays that are not affected by endogenous lipoprotein concentrations. Our CETP and lecithin:cholesterol acyltransferase (LCAT) assays are used in human clinical trials to monitor the effect of drugs on these proteins. Other areas of research include respiratory diseases.

Our Founders

Robert W. Brocia

Chief Executive Officer

Marie Dagata